One of them is the CALGB 9343 trial, which reported that the recurrence rates of older women with estrogen receptor (ER)-positive early-stage breast cancer who received endocrine therapy alone were not significantly different from those of women who received both endocrine therapy and RT (4% vs 1%) [6]. This evidence concerns the gene ESR1 and breast carcinoma.